Clinical Trial

Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

Study acronym: R-S-
Completed Phase 1
View on ClinicalTrials.gov →
Summary
Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA has been investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-25; most recent amendment 2026-05-14.
Status change: Recruiting → Completed 2026-05-14
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT06905652
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Healthy
Enrollment 26 participants
Start Date 2025-07-29
Primary Completion 2026-05-12 (estimated)
Study Completion 2026-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-15